IntraBio's Levacetylleucine Shows Strong Efficacy in Ataxia-Telangiectasia Trial
Event summary
- IntraBio's Phase III trial of levacetylleucine in Ataxia-Telangiectasia patients showed a statistically significant -1.92 point improvement on the SARA scale vs. placebo (p<0.001).
- Secondary endpoints also met, with improvements on ICARS (-4.22 vs. -1.69) and CGI-I (-0.6 vs. -0.2).
- Levacetylleucine was well-tolerated with no drug-related serious adverse events.
- IntraBio plans immediate regulatory submissions to FDA, EMA, and other global authorities for label expansion.
The big picture
This represents IntraBio's second successful Phase III trial for levacetylleucine, following its approval for Niemann-Pick disease Type C. The consistent efficacy across multiple rare neurological diseases positions the company as a specialist in amino acid-based therapies. With approximately 9,600 diagnosed A-T patients in key markets, this potential new indication could significantly expand IntraBio's commercial footprint.
What we're watching
- Regulatory Pathway
- The pace at which FDA and EMA will review the label expansion application for levacetylleucine in A-T.
- Commercial Strategy
- How IntraBio plans to position this potential new indication alongside its existing NPC approval.
- Pipeline Expansion
- Whether these results will accelerate development of levacetylleucine in other neurodegenerative indications.